Merck (MRK) Misses Q1 EPS by 23c, Offers FY Guidance

Merck (NYSE: MRK) reported Q1 EPS of $1.40, $0.23 worse than the analyst estimate of $1.63. Revenue for the quarter came in at $12.1 billion versus the consensus estimate of $12.66 billion.

GUIDANCE:

Merck sees FY2021 EPS of $6.48-$6.68, versus the consensus of $6.58. Merck sees FY2021 revenue of $51.8-53.8 billion, versus the consensus of $52.51 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
• Merck's remigromig meets primary endpoint in DME phase 2b/3 trial
• Costco (COST) Tops Q4 EPS by 20c